STAT6 PROTAC

STAT6 PROTAC refers to a series of orally bioavailable proteolysis-targeting chimeras (PROTACs) developed by Peak Perform Innova Shanghai Biotechnology to selectively degrade Signal Transducer and Activator of Transcription 6 (STAT6). These molecules function by inducing the formation of a ternary complex between STAT6 and the cereblon (CRBN) E3 ubiquitin ligase, leading to the ubiquitination and subsequent proteasomal degradation of STAT6. By targeting the SH2 domain of STAT6 at a site distinct from the IL-4Rα-binding pocket, these degraders potently inhibit IL-4 and IL-13 signaling, which are central drivers of Type 2 immunity. Preclinical data demonstrate that these molecules effectively block the release of inflammatory biomarkers such as TARC (CCL17) and periostin, suggesting potential therapeutic utility in allergic diseases such as asthma and atopic dermatitis.

Other names

STAT6 degraderSTAT-6 degraderSTAT 6 degrader